Search results
Results from the WOW.Com Content Network
Epoetin alfa, sold under the brand name Epogen among others, is a human erythropoietin produced in cell culture using recombinant DNA technology. [ 8 ] [ 9 ] Epoetin alfa is an erythropoiesis-stimulating agent. [ 8 ]
n/a n/a Ensembl n/a n/a UniProt n a n/a RefSeq (mRNA) n/a n/a RefSeq (protein) n/a n/a Location (UCSC) n/a n/a PubMed search n/a n/a Wikidata View/Edit Human Erythropoietin (/ ɪ ˌ r ɪ θ r oʊ ˈ p ɔɪ. ɪ t ɪ n, - r ə -, - p ɔɪ ˈ ɛ t ɪ n, - ˈ iː t ɪ n / ; EPO), also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidneys ...
It is unclear if use is safe during pregnancy. [5] [6] They work similar to naturally occurring erythropoietin. [1] They were first approved for medical use in the United States in 1989. [5] It is on the World Health Organization's List of Essential Medicines. [7] Commercially available agents include epoetin alfa and darbepoetin alfa, and ...
Preterm infants are often anemic and typically experience heavy blood losses from frequent laboratory testing in the first few weeks of life. [4] Although their anemia is multifactorial, repeated blood sampling and reduced erythropoiesis with extremely low serum levels of erythropoietin (EPO) are major causative factors.
Estrogen, progesterone, and human chorionic gonadotropin (hCG) levels throughout pregnancy. Estrogen, progesterone, and 17α-hydroxyprogesterone (17α-OHP) levels during pregnancy in women. [ 1 ] The dashed vertical lines separate the trimesters .
In response to these advisories, the FDA released a Public Health Advisory [14] on 9 March 2007, and a clinical alert [15] for doctors on 16 February 2007, about the use of erythropoeisis-stimulating agents (ESAs) such as epoetin alfa (marketed as Epogen) and darbepoetin alfa. The advisory recommended caution in using these agents in cancer ...
In 1983 his team successfully established the gene coding for it [2] and recombinant human erythropoietin was approved by the US FDA in June 1989 [3] with the generic name epoetin alpha, tradename Epogen. [4] [5] Lin was also engaged in developing novel pharmaceutics and studying their molecular mechanisms.
Epoetin beta (), sold under the brand name Neorecormon among others, is a synthetic, recombinant [4] form of erythropoietin, a protein that promotes the production of red blood cells.